Congress strips vaccine makers' legal shield, opening door to unlimited lawsuits

What it does

This bill strips away federal legal protections that currently shield COVID-19 vaccine manufacturers from lawsuits. It voids three specific federal statutes that grant manufacturers immunity or limit their liability, allowing individuals to sue vaccine makers directly for any harm they claim resulted from vaccination—even if they already received compensation through existing federal injury programs. The bill applies retroactively to all COVID-19 vaccines ever administered.

Why we flagged it

The bill's sole operative mechanism is the repeal of federal immunity and liability-limit statutes specific to COVID-19 vaccine makers. It is a direct liability expansion, not a public-health measure or safety standard—it creates legal exposure without mandating any change to vaccine design, testing, or safety protocols.

What the text implies

• Retroactive applicability exposes manufacturers to claims for vaccines administered years ago, potentially decades after administration, creating tail liability that may not have been priced into original liability insurance or reserves.
• Stacking provision (subsection c) allows individuals to collect from federal injury programs AND sue manufacturers simultaneously, creating double-recovery risk that may overwhelm manufacturers' insurance and capital.
• Removal of liability protections may chill vaccine development for future pandemics if manufacturers cannot obtain affordable liability insurance or face uninsurable tail risk.
• The bill does not establish a causation standard, burden of proof, or damages cap, leaving manufacturers exposed to speculative or remote-causation claims that federal programs screen out.

Section numbers refer to the bill text the analysis read — linked under Primary records below.

Who it affects

Citizens gain a new legal remedy (direct suit against manufacturers) and are explicitly permitted to stack compensation (federal programs PLUS civil litigation), which expands access to recovery. However, removing manufacturer liability protections may reduce vaccine supply, increase prices, or discourage future vaccine development—effects that could harm public health and access to vaccines during future pandemics. The bill creates a genuine trade-off between individual remedy and collective va

Who stands to gain

• personal injury law firms
• litigation funders
• class-action attorneys

Named in the bill

COVID-19 vaccine manufacturers, Food and Drug Administration (FDA), Public Health Service Act (sections 319F-3, 2111, 2122, 319F-4), Countermeasures Injury Compensation Program, National Vaccine Injury Compensation Program, House Committee on the Judiciary

Where it stands

11 cosponsors: 11 Republicans.

• Feb 18, 2025 — Introduced · Congress.gov: “Introduced in House”
• Feb 18, 2025 — Referred to House Committee on the Judiciary · Congress.gov: “Referred to the House Committee on the Judiciary”

Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.

Money around this bill

2 lobbying clients named this bill on 4 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $1,540,000 in lobbying spend. A filing names 52 bills on average, so that figure is what each filing reported, not a share belonging to this bill.

More lobbying clients named this bill than 41% of bills with at least one filing.

Chip Roy, the sponsor, reported $68,100 in PAC receipts in the 2026 cycle.

• AFL-CIO — $1,520,000 on 2 filings
• American Tort Reform Association — $20,000 on 2 filings

Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.